Oseltamivir, an Influenza Neuraminidase Inhibitor Drug, Does Not Affect the Steady-state Pharmacokinetic Characteristics of Cyclosporine, Mycophenolate, or Tacrolimus in Adult Renal Transplant Patients.
Lam H, Jeffery J, et al.Therapeutic Drug Monitoring, 33(6): 699-704, 2011.
Aims
To determine whether oseltamivir, an influenza neuraminidase inhibitor drug would or not affect the steady-state pharmacokinetics of cyclosporine, mycophenolate, or tacrolimus in renal transplant patients.
Interventions
A single 75 mg dose of oseltamivir versus no oseltamivir. All patients received mycophenolate, cyclosporine or tacrolimus.
Participants
19 renal transplant recipients.
Outcomes
Total plasma/blood drug concentration, trough blood concentration, maximum observed plasma concentration (Cmax), observed time to Cmax (Tmax), area under the concentration versus time curve (AUC), adverse symptoms, total white blood cell, hemoglobin and platelet concentrations, serum concentrations of creatinine, sodium, potassium, chloride, bicarbonate, glucose, direct and total bilirubin, alanine aspartate and gamma glutamyl transferases and albumin.
Follow-up
48 hours
CET Conclusions
Oseltamivir (Os) is effective and safe for both prophylaxis and therapy for influenza A and B. It is used in the renal transplant population and hence this study is important. It is a randomised crossover study and suggests that co-administration of Os does not cause adverse symptoms nor alter the steady state pharmacokinetics of cyclosporine A, mycophenolate mofetil or tacrolimus in stable adult renal transplant patients with mild renal insufficiency.
Data analysis
Per protocol analysis
Trial registration
Not reported